NLRP3 Inflammasome Inhibitor I

Research use only, not for human use.

It is a NLRP3 Inflammasome Inhibitor I.

It is a NLRP3 Inflammasome Inhibitor I.

——

NLRP3-IN-2 is well tolerated with no effects on the glucose levels in vivo.NLRP3-IN-2 (100 mg/kg) treatment in a model of AMI due to ischemia+reperfusion significantly inhibits the activity of inflammasome (caspase-1) in the heart by 90% (P<0.01) and reduced infarct size, measured at pathology (by >40%, P<0.01) and with troponin I levels (by >70%, P<0.01) . Animal Model:Experimental acute myocardial infarction (AMI) model in mice.Dosage:100 mg/kg.Administration:Intraperitoneal administration 30 minutes prior to surgery, then every 6 hours for 3 additional doses.Result:Led to a significant >90% reduction in caspase-1 activity (reflective of the formation of an active inflammasome) in the heart tissue measured 24 hours after ischemia. Led to a significant reduction in the infarct size measured with TTC (>40% reduction) or troponin I levels (>70% reduction) when compared with vehicle alone.

Glibenclamide impurity A | Glibenclamide A | Glyburide Related Compound A | NLRP3 Inflammasome Inhibitor I

NF-κB

NOD

NLRP3

——

——

16673-34-0

368.83

C16H17ClN2O4S

>98% (HPLC)

Soluble in DMSO

O=C(NCCC1=CC=C(S(=O)(N)=O)C=C1)C2=CC(Cl)=CC=C2OC

5-Chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide

(-20℃)

With Ice Pack

≥ 2 years